about
Development of HPLC-UV method for rapid and sensitive analysis of topically applied tetracaine: its comparison with a CZE method.Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazolePharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method.Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studyRepression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function
P50
Q35174137-5D1CE9EB-61F9-4AFD-ACCB-DDB6CE1E9439Q36806598-5282FBFC-FD46-4FC6-B38B-61C786D7A76CQ37471097-F9003194-B5E2-4EE0-8B64-02C124625A20Q38673319-A421A576-3929-4070-8937-AE47E68C4909Q38920450-2FC29B95-F4E4-4C4B-B8AB-EF4B60B03DEFQ38959134-C10C05B0-0F2C-4329-9B29-324B110A3EB0Q39029664-7802CE05-8B60-4266-80B0-DD6A1C539D0FQ39036639-219F0411-1389-4D1E-B98F-80FED1FE32A1Q39052828-11F3AF0F-C742-4BC6-93B9-48C0A8A234E8Q39648670-E590B5B5-4AC2-40DF-9866-62EF51DA2BCAQ41036166-71D86582-01A2-43CA-8069-510E5EBD6456Q42369564-883468C8-158E-4F64-9027-CCC09BD71807Q47148137-9B2F012F-F5C6-4CBF-9143-41323E01BA43Q54207519-90F632F2-7E28-4F9C-A4FB-E76DE2190FC0Q57683767-324F3FEE-75A4-4F8F-B441-2511F8B02A36Q90244336-476B8EE7-E123-4372-A9D4-839FD47C6ABF
P50
description
researcher, ORCID id # 0000-0003-4368-8565
@en
wetenschapper
@nl
name
Essam Ghazaly
@ast
Essam Ghazaly
@en
Essam Ghazaly
@es
Essam Ghazaly
@nl
type
label
Essam Ghazaly
@ast
Essam Ghazaly
@en
Essam Ghazaly
@es
Essam Ghazaly
@nl
prefLabel
Essam Ghazaly
@ast
Essam Ghazaly
@en
Essam Ghazaly
@es
Essam Ghazaly
@nl
P106
P1153
35975956900
P31
P496
0000-0003-4368-8565